As of 2025-06-18, the Intrinsic Value of SkinBioTherapeutics PLC (SBTX.L) is (3,846.64) GBP. This SBTX.L valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 16.62 GBP, the upside of SkinBioTherapeutics PLC is -23,237.70%.
The range of the Intrinsic Value is (11,402.38) - (2,328.97) GBP
Based on its market price of 16.62 GBP and our intrinsic valuation, SkinBioTherapeutics PLC (SBTX.L) is overvalued by 23,237.70%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (11,402.38) - (2,328.97) | (3,846.64) | -23237.7% |
| DCF (Growth 10y) | (46,350.10) - (245,358.22) | (79,588.80) | -478829.7% |
| DCF (EBITDA 5y) | (797.02) - (1,071.06) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (16,512.00) - (24,001.96) | (1,234.50) | -123450.0% |
| Fair Value | -5.06 - -5.06 | -5.06 | -130.44% |
| P/E | (13.54) - (13.87) | (13.61) | -181.9% |
| EV/EBITDA | (6.12) - (7.05) | (6.43) | -138.6% |
| EPV | (2.59) - (3.52) | (3.05) | -118.4% |
| DDM - Stable | (13.76) - (89.71) | (51.74) | -411.2% |
| DDM - Multi | (1,545.96) - (7,845.08) | (2,584.72) | -15647.2% |
| Market Cap (mil) | 42.30 |
| Beta | 1.56 |
| Outstanding shares (mil) | 2.54 |
| Enterprise Value (mil) | 42.09 |
| Market risk premium | 5.98% |
| Cost of Equity | 7.08% |
| Cost of Debt | 7.00% |
| WACC | 7.07% |